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Abstract
Purpose Pasireotide long-acting release is a somatostatin
analog that is indicated for treatment of patients with
acromegaly. This analysis documents the safety of pasir-
eotide long-acting release in patients with acromegaly
enrolled in the ACCESS trial (ClinicalTrials.gov identiﬁer:
NCT01995734).
Methods ACCESS is an open-label, multicenter, single-
arm, expanded-treatment protocol designed to provide
patients access to pasireotide long-acting release pending
regulatory approval. Patients received pasireotide long-
acting release 40 mg administered intramuscularly every
28 days. The primary outcome was the proportion of
patients having a treatment-emergent grade ≥3 or serious
adverse event. Efﬁcacy data were not collected.
Results Forty-four adult patients with active acromegaly
were enrolled in the study for an average of 37.6 weeks
(range, 4–70 weeks). Twenty-ﬁve grade ≥3 treatment-
emergent adverse events were reported in 11 patients
(25.0 %), 3 of whom (27.3 %) experienced grade ≥3
hyperglycemia. In patients treated with pasireotide long-
acting release for ≥3 months (n= 42), mean glycated
hemoglobin and fasting plasma glucose levels increased
signiﬁcantly from 5.9 % and 100.4 mg/dL at baseline to
6.8 % and 135.9 mg/dL at 3 months, respectively. Ten
patients (22.7 %) were treated with pasireotide long-acting
release for ≥15 months, after which mean glycated hemo-
globin and fasting plasma glucose levels were 6.3 % and
123 mg/dL, respectively. Twenty-one patients (48 %) initi-
ated antidiabetic medication.
Conclusions Grade ≥3 adverse events (primary outcome)
were reported in 25.0 % of acromegaly patients treated with
pasireotide long-acting release in a clinical setting.
Hyperglycemia-related adverse events were reported in 45.5%
of patients, but were typically manageable, supporting the
role of pasireotide long-acting release as a safe treatment
option for acromegaly patients.
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Introduction
Acromegaly is a rare disorder that, in the large majority of
cases, is caused by hypersecretion of growth hormone (GH)
from a benign somatotroph pituitary adenoma, which leads
to elevated insulin-like growth factor 1 (IGF-1) secretion
[1–3]. Excessive GH and IGF-1 levels (>1 ng/mL and >age
and sex-normalized IGF-1 levels above the upper limit of
normal, respectively) are associated with multisystemic
comorbidities, including congestive heart failure, sleep
apnea, arthritis, impaired glucose tolerance, insulin resis-
tance, and diabetes mellitus, as well as an elevated risk of
mortality [1, 2, 4]. Treatment that achieves and maintains
biochemical control is associated with the improvement of
some key comorbidities and leads to normalization of life
expectancy [1, 2, 5]. Additionally, sustained reductions in
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pituitary tumor volume and signs and symptoms of disease
are important goals in the treatment of acromegaly [1, 2].
Transsphenoidal surgery is the ﬁrst-line treatment for
acromegaly [2, 3, 6]. Because approximately 75 % of GH-
secreting tumors are macroadenomas that invade the
cavernous sinus or extend into the suprasellar region [7],
most patients will not achieve complete remission from
surgery alone and, therefore, will need pharmacological
intervention [2].
Somatostatin receptor types 2 and 5 (sst2 and sst5) are
each expressed in approximately 90 % of GH-secreting
pituitary adenomas and have been useful for tumor-targeted
pharmacotherapy with ﬁrst-generation somatostatin analogs
[SSAs; octreotide long-acting release (LAR) and lanreotide
Autogel (ATG)] [8–13]. Pasireotide LAR is a second-gen-
eration, multireceptor-targeted SSA that is approved by the
US Food and Drug Administration, the European Medicines
Agency, and several South American countries for the
treatment of patients with acromegaly who have had an
inadequate response to surgery and/or for whom surgery is
not an option [14–17]. Compared with octreotide LAR and
lanreotide ATG, which bind with highest afﬁnity to sst2,
pasireotide has higher binding afﬁnity for sst5 [14, 18, 19].
In a large, randomized, 12-month, Phase 3 trial
(C2305 study) in medically naive patients with acromegaly,
pasireotide LAR demonstrated superior biochemical control
(composite end point of age-normalized IGF-1 and GH
<2.5 ng/mL) in comparison with octreotide LAR (31.3 vs.
19.2 %; P= 0.007) [20]. Similar results were obtained in the
12-month crossover extension phase of the C2305 trial, in
which 17.3 % (95 % conﬁdence interval, 9.8–27.3) of
patients with acromegaly who had not achieved biochem-
ical control with octreotide LAR achieved biochemical
control with pasireotide LAR [21]. In a separate, large,
randomized, 24-week, Phase 3 trial (C2402 study) in
patients with inadequately controlled acromegaly, treatment
with two different doses of pasireotide LAR resulted in
signiﬁcantly higher rates of biochemical control than did
continued treatment with either octreotide LAR or lanreo-
tide ATG (15% of patients treated with pasireotide LAR
40 mg and 20 % of those treated with pasireotide LAR
60 mg vs. 0 % of those continuing treatment with octreotide
LAR or lanreotide ATG; P= 0.0006 for pasireotide LAR
40 mg group, P< 0.0001 for pasireotide LAR 60mg group)
[22].
In both of these large Phase 3 trials, treatment with
pasireotide LAR was associated with higher rates of
hyperglycemia-related adverse events (AEs) than were other
SSAs [20, 22]. In the C2305 trial, the rate of
hyperglycemia-related AEs was 57.3 % in patients treated
with pasireotide LAR and 21.7 % in patients treated with
octreotide LAR [20]. Grade 3/4 hyperglycemia-related AEs
were reported in 9.0 % of patients treated with pasireotide
LAR and in 1.7 % of those treated with octreotide LAR.
AEs related to elevations in blood glucose were the most
common causes of discontinuation in the pasireotide LAR
group. In the C2402 trial, hyperglycemia-related AEs were
reported in 67 % of patients treated with pasireotide LAR
40 mg, in 61 % of those treated with pasireotide LAR
60 mg, and in 30 % of those who continued treatment with
active control [22]. In those patients with normal glycemic
levels at baseline, 30 % of patients treated with pasireotide
LAR 40 mg developed hyperglycemia compared with 48 %
of patients treated with pasireotide LAR 60 mg and 15 % of
patients treated with the active control [23]. In contrast, in
patients with hyperglycemia at baseline, 52 % maintained
elevated glycemic levels after 24 months of treatment with
pasireotide LAR 40 mg, compared with 71 % of patients
treated with pasireotide LAR 60mg and 42 % of patients
treated with the active control. Here we present safety data
from an expanded-treatment protocol that evaluated pasir-
eotide LAR in a clinical practice-based setting, with a focus
on the reported incidence of hyperglycemia-related AEs.
Materials and methods
Patients
Patients were eligible for inclusion in the study if they met
the following inclusion criteria: age ≥18 years; conﬁrmed
diagnosis of acromegaly that was caused by a GH-
producing pituitary tumor, with circulating age and sex-
adjusted IGF-1 levels >1.3 × the upper limit of normal and
random GH concentrations >1 µg/mL within 30 days of
screening; not controlled by, not eligible for, or refused
pituitary surgery; and had Karnofsky performance status
scores of >60. A washout period of ≥8 weeks (days −63 to 0)
was required before the screening assessment for patients
who were receiving medical therapy for acromegaly.
Key exclusion criteria included concomitant treatment
with SSAs, GH-receptor antagonists, or dopamine agonists,
unless concomitant treatment was discontinued and the
washout period was completed before the screening
assessment; compression of the optic chiasm that caused
any visual ﬁeld defect for which surgical intervention was
indicated; signs or symptoms of tumor compression for
which surgical intervention was required; major surgery/
surgical therapy of any type within 4 weeks of screening;
radiotherapy of the pituitary gland within 4 weeks before
screening or failure to recover from side effects of radio-
therapy; history of hypothyroidism that was inadequately
treated with thyroid hormone replacement therapy; or dia-
betes with poorly controlled blood glucose, as evidenced by
glycated hemoglobin (HbA1c) >8 % at screening.
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Study design
ACCESS was designed as an open-label, uncontrolled,
single-arm, multicenter, expanded-treatment protocol to
provide access to pasireotide LAR to patients with acro-
megaly for whom medical therapy was appropriate pending
regulatory approval. After a screening period, which may
have included a 4–8-week washout period for patients
previously treated with medical therapy, eligible patients
were administered pasireotide LAR 40 mg intramuscularly
starting at visit 2 (baseline/week 0) every 28 days (±2 days)
until either a discontinuation occurred or pasireotide LAR
became both commercially available and reimbursable.
Patients were to be transitioned to commercial pasireotide
LAR as quickly as possible (not exceeding 6 months after
commercial availability) and to have end-of-treatment eva-
luations on the day of the ﬁnal dose of the study. For
patients who discontinued treatment, follow-up evaluations
were performed 28 days after the last administration of
study drug.
At the study investigator’s discretion, the dose of pasir-
eotide LAR could be increased to 60 mg for patients with
age and sex-adjusted IGF-1 levels greater than the upper
limit of normal after the third injection of pasireotide LAR
40 mg. Stepwise dose reductions from 60 to 40 mg and from
40 to 20 mg were permitted for tolerability (e.g., grade ≥ 3
AE or laboratory change directly attributable to pasireotide
LAR).
The study was conducted in accordance with the ethical
principles of the Declaration of Helsinki and implemented
and reported in accordance with the International Con-
ference on Harmonisation Harmonised Tripartite Guideline
for Good Clinical Practice. The study protocol and informed
consent forms were approved by the institutional review
board, independent ethics committee, and/or research ethics
board of each study site. All patients provided written
informed consent to participate in the trial (ClinicalTrials.
gov identiﬁer: NCT01995734).
Outcomes
The primary objective was to document the safety of
pasireotide LAR in patients with acromegaly by determin-
ing the proportion of patients with treatment-emergent
grade ≥3 or serious AEs. Efﬁcacy data were not collected
centrally for this study. Secondary end points included the
incidence of AEs; abnormalities in laboratory, vital signs, or
electrocardiographic (ECG) results; and changes from
baseline in laboratory values, ECG results, and vital signs.
Investigators were responsible for evaluating IGF-1 and GH
every 3 months to determine whether dose modiﬁcations
were needed; however, the data were not collected by the
sponsor.
Treatment assessments
The severity of AEs was described as mild (grade 1),
moderate (grade 2), severe (grade 3), or life-threatening
(grade 4) according to the Common Terminology Criteria
for Adverse Events (CTCAE) [24]. The CTCAE is a set of
criteria used for the standardized grading of AEs. Notably,
hyperglycemia is deﬁned and graded by the CTCAE
according to fasting plasma glucose (FPG) level as follows:
grade 1, greater than the upper limit of normal to 160 mg/
dL; grade 2, >160–250 mg/dL; grade 3, >250–500 mg/dL;
and grade 4, >500 mg/dL. Serious AEs included those that
were fatal or life-threatening; resulted in persistent or sig-
niﬁcant disability; were associated with a congenital
anomaly or birth defect; jeopardized the patient; or may
have required medical or surgical intervention, required
inpatient hospitalization, or prolonged an existing hospita-
lization. Laboratory values were regularly monitored,
including hematologic and blood chemistry parameters
(including FPG), liver function parameters, coagulation
parameters, HbA1c, free thyroxine, thyroid-stimulating
hormone, serum cortisol, plasma adrenocorticotropic hor-
mone, and urinary parameters. A standard 12-lead ECG was
performed for each patient at screening, at baseline (before
and 30 min after the ﬁrst injection), 21 days after each
injection for the ﬁrst 3 months, and every 3 months there-
after during the study. Gallbladder ultrasonography was
performed at baseline, at month 6, and at the end of
treatment.
Statistical analyses
Demographic and other baseline data (including disease
characteristics) were summarized for the complete cohort,
which included all patients who received ≥1 dose of
pasireotide LAR. All safety analyses were based on data
from patients who received ≥1 dose of pasireotide LAR and
had ≥1 postbaseline safety assessment. No sample size
calculation was performed. Primary safety data were ana-
lyzed with descriptive statistics. Categorical data are
represented as frequencies and percentages. For continuous
data, means, standard deviations (SDs), medians, mini-
mums, and maximums were estimated.
Results
Patient characteristics
A total of 79 patients were screened, and 44 were deemed
suitable candidates for inclusion in the study (Fig. 1). There
were several reasons why patients failed the initial screen,
including unacceptable laboratory or test procedure value
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(n= 15; 19.0 %), did not meet diagnostic criteria (n= 8;
10.1 %), administrative reasons (n= 8; 10.1 %), consent
withdrawal (n= 3; 3.8 %), and use of excluded medication
or inadequate washout (n= 1; 1.3 %). For the duration of
the study, 44 patients (female, 56.8 %) received treatment
for acromegaly with pasireotide LAR. The mean age was
45.5 years, and the mean body mass index was 32.9 kg/m2.
Previous diagnoses of impaired fasting glucose and diabetes
mellitus were reported in 1 patient (2.3 %) and 12 patients
(27.3 %), respectively. Patient characteristics at baseline are
presented in Table 1.
Not all patients initiated treatment with pasireotide LAR
at the same time, and the study had a ﬁxed end point (when
pasireotide LAR became commercially available and
reimbursable). Accordingly, the total treatment time ranged
from 4 to 70 weeks. Patients were treated with pasireotide
LAR for a mean duration of 37.6 weeks. A total of 43
patients (98 %) received ≥3 injections of pasireotide LAR,
with a mean of 9.8 injections per patient.
A total of 15 patients (34.1 %) had ≥1 dose increase, 4
patients (9.1 %) had a dose reduction, and 17 patients
(38.6 %) had a dose delay at some point during the study.
The initial dose per injection of pasireotide LAR was 40
mg, and the mean dose per injection over the course of the
study was 42.2 mg. Twenty-eight patients (63.6 %) com-
pleted the study, while 16 patients (36.4 %) discontinued
treatment. Of those who did not complete the study, six
patients discontinued because of an unsatisfactory ther-
apeutic effect, ﬁve because of withdrawn consent, and ﬁve
because of an AE. Hyperglycemia was listed as the reason
for treatment discontinuation for four patients.
Adverse events
Regardless of relationship to study drug, a total of 25 grade
≥3 treatment-emergent AEs were reported in 11 patients
(25.0 %). The most frequent grade ≥3 treatment-emergent
AEs were abdominal pain and elevated blood glucose,
which occurred in 3 patients each (6.8 %; Table 2). Of the
25 reported grade ≥3 or serious treatment-emergent AEs, 11
were suspected to be related to pasireotide LAR treat-
ment [elevated blood glucose (n= 3), elevated HbA1c, type
2 diabetes mellitus, abdominal pain, muscle spasms, alo-
pecia, pancreatitis, pancreatolithiasis, and cholelithiasis] and
were reported in 6 patients (13.6 %). One patient who
experienced grade 3 abdominal pain subsequently received
a diagnosis of grade 4 adenocarcinoma of the colon and
discontinued treatment with pasireotide LAR because of
treatment of colorectal cancer. The adenocarcinoma of the
colon was considered unrelated to treatment with pasireo-
tide LAR. In another patient, a grade 2 adenocarcinoma of
the colon was diagnosed only 9 days after administration of
the ﬁrst dose of pasireotide LAR, and the event was con-
sidered to be unrelated to pasireotide LAR treatment. Dur-
ing the course of treatment, all 44 patients experienced ≥1
AE of any grade, regardless of relationship to pasireotide
LAR (Table 2). A total of 20 patients (45.5 %) experienced
hyperglycemia-related AEs. Elevated blood glucose was
reported in 10 patients (22.7 %), hyperglycemia in 10
patients (22.7 %), and type 2 diabetes mellitus in 6 patients
(13.6 %). Although these three categories of AEs are tech-
nically the same, they are reported differently depending on
whether the AE was detected as a change in a laboratory
value or reported by the clinician. Aside from those related
to hyperglycemia, the most common AEs reported were
gastrointestinal-related: diarrhea in 17 patients (38.6 %),
nausea in 12 patients (27.3 %), and abdominal pain in 8
patients (18.2 %).
Hyperglycemia and diabetes
Of the 43 patients with evaluable glycemic parameters,
elevated levels of HbA1c (>6.4 %) and FPG (>99 mg/dL)
were detected at baseline in 5 (11.6 %) and 18 (41.9 %)
patients, respectively (Fig. 2). After pasireotide LAR was
initiated, HbA1c> 6.4 % and FPG> 99 mg/dL were recor-
ded at least once in 21 (48.8 %) and 43 (100 %) patients,
respectively. Low insulin levels (<5 μIU/mL) were detected
at least once after pasireotide initiation in 14 patients
Fig. 1 Patient disposition
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(32.6 %), whereas no patients had low fasting insulin at
baseline.
A total of 42 patients (95.5 %) were treated with pasir-
eotide LAR for a minimum of 3 months and had evaluable
data for glycemic parameters. Three months after initiation
of pasireotide LAR, the mean HbA1c increased from 5.9 %
at baseline to 6.8 % (P= 0.0002), and FPG increased sig-
niﬁcantly from 100.4 mg/dL at baseline to 135.9 mg/dL
(P < 0.0001; Fig. 3). In the 10 patients (22.7 %) treated with
pasireotide LAR for 15 months, mean HbA1c levels
increased from 5.8 % at baseline to 6.3 % (P= 0.1219) and
FPG levels increased signiﬁcantly from 102.4 mg/dL at
baseline to 123.2 mg/dL (P= 0.0096). Changes in glycemic
parameters were accompanied by reductions in fasting
insulin levels from a baseline level of 24.5–15.8 μIU/mL at
3 months (P= 0.1147). In the 10 patients treated with
pasireotide LAR for 15 months, fasting insulin levels were
28.2 μIU/mL at baseline and 19.8 μIU/mL at 15 months
(P= 0.6079).
Twenty-one patients (47.7 %) initiated new antidiabetic
medication on the same day as or after the ﬁrst dose of
pasireotide LAR (Table 3). A range of antidiabetic medi-
cations were administered including metformin (n= 17),
sitagliptin (n= 7), any form of insulin (n= 3), glimepiride
(n= 3), linagliptin (n= 1), liraglutide (n= 1), repaglinide
(n= 1), PolyGlycopleX® (an over-the-counter supplement,
n= 1), and canagliﬂozin (n= 1).
Discussion
Phase 3 studies evaluating the efﬁcacy and safety of
pasireotide LAR in patients with acromegaly have













Minor signs or symptoms of disease 15 (34.1)
Normal activity with effort; some signs of disease 8 (18.2)
Cares for self; unable to carry on normal activity 3 (6.8)
Requires occasional assistance but cares for most of
own needs
2 (4.5)
Time from diagnosis to ﬁrst pasireotide dose, mean
(SD), mob
63.6 (75.5)
Prior pituitary surgery 36 (81.8)
Time from latest pituitary surgery to ﬁrst pasireotide
dose, mean (SD), moc
62.8 (60.6)
Prior pituitary irradiation 9 (20.5)
Time from latest pituitary irradiation to ﬁrst
pasireotide dose, mean (SD), mod
36.8 (36.7)
Prior medication for acromegaly 33 (75.0)
Prior medication administered within 60 d of study
start
11 (33.3)











a Unless otherwise noted
b Forty-three patients were included in the analysis
c Thirty-six patients were included in the analysis
d Nine patients were included in the analysis
e Thirty-three patients were included in the analysis
Table 2 Most common AEs in the ACCESS study (observed with
frequency ≥7 %)
Number of events, n (%)
Treatment-
emergent AEa
Grade 1 Grade 2 Grade 3 Total
(n= 44)
Diarrhea 13 (29.5) 4 (9.1) 0 17 (38.6)
Nausea 5 (11.4) 6 (13.6) 1 (2.3) 12 (27.3)
Hyperglycemiab 5 (11.4) 5 (11.4) 0 10 (22.7)
Elevated blood
glucoseb
5 (11.4) 2 (4.5) 3 (6.8) 10 (22.7)
Abdominal pain 4 (9.1) 1 (2.3) 3 (6.8) 8 (18.2)
Cholelithiasis 8 (18.2) 0 0 8 (18.2)
Nasopharyngitis 7 (15.9) 0 0 7 (15.9)
Fatigue 4 (9.1) 1 (2.3) 1 (2.3) 6 (13.6)
Hypoglycemia 5 (11.4) 1 (2.3) 0 6 (13.6)
Type 2 diabetes
mellitus
4 (9.1) 1 (2.3) 1 (2.3) 6 (13.6)
Vomiting 3 (6.8) 2 (4.5) 1 (2.3) 6 (13.6)
Dizziness 5 (11.4) 0 0 5 (11.4)
AE adverse event
a No grade 4 AEs were reported in the below categories
b For technical reasons, AEs related to hyperglycemia were designated
as either “elevated blood glucose” if determined only by laboratory
values or as “hyperglycemia” if reported by the clinician















































Fig. 2 Frequency of patients with ≥1 instance of abnormal glycemic
parameters after initiation of pasireotide LAR. a Analysis included 43
patients who had evaluable glycemic levels at baseline. b Normal
ranges: FPG, 70–99 mg/dL; insulin, 5–15 µIU/mL; HbA1c, 0–6.4 %.
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Fig. 3 Monthly assessments of a FPG and b HbA1c during the course
of treatment with pasireotide LAR. Dotted lines represent the upper
limit of the normal range (FPG, 99 mg/dL; HbA1c, 6.4 %). Markers
represent the mean values, and the area of each marker is proportional
to the number of patients assessed at each month. Error bars represent
the standard deviation. Not all patients initiated treatment with
pasireotide LAR at the same time, and the study had a ﬁxed end point
(when pasireotide LAR became commercially available and reimbur-
sable). Accordingly, fewer patients being evaluated at latter visits
occurred primarily because of the different treatment initiation times
for individual patients. BL baseline
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demonstrated higher rates of hyperglycemia-related AEs in
patients treated with pasireotide LAR than in patients trea-
ted with octreotide LAR or lanreotide ATG [20, 22]. The
ACCESS study was designed as an expanded-treatment
protocol that would permit assessment of the safety of
pasireotide LAR in patients with acromegaly within a
practice-based setting before the drug became commercially
available. The mean duration of treatment was 37.6 weeks,
with a mean of 9.8 injections of pasireotide LAR. Our
analysis demonstrated a low rate of grade ≥3 or serious
treatment-emergent AEs (the primary end point of the
study), which occurred in 25.0% of patients, and only 11.4%
of patients discontinued treatment because of AEs, but
45.5 % experienced hyperglycemia-related AEs. A total of
four patients (9.1 %) discontinued treatment with pasireo-
tide LAR because of hyperglycemia-related AEs. Among
patients who were treated with antidiabetic therapy, most
(66.7 %) initiated only ﬁrst-line antidiabetic medications
(e.g., metformin, sitagliptin). These results suggest that
hyperglycemia-related AEs associated with pasireotide
LAR may be manageable with standard antidiabetic medi-
cation. Of note, <50 % of patients initiated antidiabetic
therapy after starting treatment with pasireotide LAR.
In the patients treated with pasireotide LAR for at least
3 months (n= 42), elevations in HbA1c and FPG to diabetic
levels (HbA1c >6.4 %, FPG >99 mg/dL) were observed in
40 % (n= 17) and 93 % (n= 39) of patients, respectively,
which is consistent with previous ﬁndings [20, 22].
Similarly, in patients who completed ≥15 months of the
study (n= 10), diabetic HbA1c levels (>6.4 %) were
reported in 40 % (n= 4). Most patients treated with pasir-
eotide LAR, regardless of glucose tolerance at baseline,
experience elevated glucose levels within the ﬁrst 2 to
3 months [14], which typically stabilize thereafter [26].
Therefore, since the majority of patients in the ACCESS
study (98 %) received ≥3 doses of pasireotide LAR, the
study observation period was likely long enough to allow
for appropriate treatment decisions for the management of
hyperglycemia related to pasireotide LAR.
Treatment-emergent elevated glucose levels, hypergly-
cemia, and type 2 diabetes were reported in 23 (n= 10), 23
(n= 10), and 14 % (n= 6) of patients, respectively. How-
ever, it should be noted that there is no technical difference
between these categories of AEs, except that they are
reported differently depending on whether the AE was
detected as a change in a laboratory value or was reported
by the clinician. To avoid any possibility of inaccurate
reporting of the data, the results herein are described exactly
as they were recorded in the study (i.e., a distinction was
made between “elevated glucose levels” and “hyperglyce-
mia”), similar to the published report of the C2402 study
data [22].
The optimal management of hyperglycemia associated
with pasireotide LAR in patients with acromegaly is cur-
rently being investigated [27, 28]. Of the patients in the
ACCESS trial who initiated a new antidiabetic medication,
metformin, insulin, glimepiride, and sitagliptin were the
drugs most commonly administered. A mechanistic study in
healthy volunteers showed that hyperglycemia associated
with pasireotide subcutaneous (SC) is associated with
decreases in insulin secretion but little change in insulin
sensitivity [29]. These ﬁndings are consistent with the data
presented here, which show a reduction in fasting insulin
levels after initiation of pasireotide LAR. In another study
of healthy volunteers, treatment with the biguanide met-
formin was shown to have minimal effects on hyperglyce-
mia associated with pasireotide SC exposure after an oral-
glucose-tolerance test, whereas the dipeptidyl peptidase-4
inhibitor vildagliptin and the glucagon-like peptide-1
receptor agonist liraglutide were the most effective at
restoring glucose to normal levels [30]. However, a reduc-
tion in insulin sensitivity is associated with uncontrolled
acromegaly [31]; therefore, it has been suggested that
initiating antidiabetic medications that improve insulin
sensitivity, such as metformin, may also be an effective
strategy for managing pasireotide LAR-associated hyper-
glycemia in patients with acromegaly [32]. A post hoc
analysis of patients enrolled in the C2305 trial showed that
mean HbA1c levels after 12 months of treatment with
pasireotide LAR were 6.6, 6.7 and 7.2 % in patients whose
hyperglycemia was managed with metformin alone,

















a instances in which medication was initiated before and continued
throughout treatment with pasireotide are excluded. Patients may have
taken >1 new antidiabetic medication after pasireotide LAR initiation
b includes any type of fast, intermediate, or long-acting insulin
c PolyGlycopleX is an over-the-counter ﬁber supplement that is
marketed as an aid to help balance blood sugar [25]
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metformin plus other oral antidiabetic medications, and
insulin with or without other oral antidiabetic, respectively
[27]. These data suggest that metformin may be an effective
component in pharmacological control of hyperglycemia
associated with pasireotide LAR in selected patients.
This analysis of the ACCESS study provides the ﬁrst
assessment of the safety of pasireotide LAR in a practice-
based clinical setting and reﬂects actual management pat-
terns in a broader population of patients with acromegaly.
Limitations of this analysis include an overall small number
of patients enrolled in ACCESS who had long durations of
time in the trial because of late enrollment in the study, and
the lack of speciﬁc information regarding doses of con-
comitant antidiabetic medications.
ACCESS was designed as a safety study, and efﬁcacy
data were not recorded as part of the trial design; therefore,
correlations between safety and treatment outcomes could
not be evaluated. However, previous Phase 3 studies have
investigated the efﬁcacy of pasireotide LAR [20, 22]. The
study of 358 medically naive patients with acromegaly
demonstrated that pasireotide LAR provided biochemical
control superior to that of octreotide LAR [20]. Subse-
quently, a study of 198 patients with inadequately con-
trolled acromegaly showed that treatment with pasireotide
LAR resulted in signiﬁcantly higher rates of biochemical
control than did continued treatment with other SSAs [22].
Although efﬁcacy data support the use of pasireotide LAR
in the treatment of acromegaly, particularly for patients who
fail multimodal treatment, the adverse effects of pasireotide
LAR on glycemic levels need to be taken into account when
choosing a treatment strategy [33]. The results reported here
provide evidence to support the manageable safety proﬁle
of pasireotide LAR in patients with acromegaly, which is
critical to assessing the overall clinical beneﬁt of treatment
with pasireotide LAR.
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